ClinicalTrials.gg
CompletedNCT01595009Updated Nov 29, 2018Results posted

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

A Phase 4 interventional study of Everolimus (RAD001) in Neuroendocrine Tumors, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
246
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing everolimus in Neuroendocrine Tumors — 1 open to participants now, 2 under way, none of them phase 3. Everolimus · Neuroendocrine Tumors.

Enrollment
2nd of 22
246 · median 38
Started
2011
with 2 others
Phase 4
3 of 22
none open now
Registered
12th of 22
by date
Lead sponsor
8 of 22
Novartis Pharmaceuticals

Among the 22 studies testing everolimus in Neuroendocrine Tumors, this one is the 2nd largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 4, and was the 12th registered.

Neuroendocrine Tumors

543 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

1 of the 22 studies testing everolimus in Neuroendocrine Tumors is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing everolimus in Neuroendocrine Tumors, or all of them as a file.
02

Study summary

This record combines the results of CRAD001K24133 and CRAD001K24133E1. The purpose of the CRAD001K24133 study was to evaluate the safety profile of everolimus in patients with advanced neuroendocrine tumors of pancreatic origin (pNETs) and to provide access of everolimus to this patient population. Everolimus was taken by participants until disease progression, unacceptable toxicity, death, discontinuation from the trial for any other reason, or when it became commercially available for this indication, or until May 30, 2012, whichever came first. Prior to amendment 1, the study enrolled participants with NET of the lung (L-NETs) and gastrointestinal (GI) (GI-NETs) origin. The core study was stopped (per protocol) because everolimus was approved for pNETs. All ongoing patients with pNETs were switched to commercially available everolimus. For GI and lung NETs, everolimus was not approved at the time the core study was stopped. Therefore, patients with GI or lung NETs were not able to switch to commercial drug. To provide study medication access to these patients beyond 30 May 2012, the open label extension study, CRAD001K24133E1, was conducted. In the extension study, RAD001K24133E1, participants with GI or lung NETs who had not progressed during therapy with everolimus in the core study and who had not suffered from intolerable toxicity, were enrolled and treated with everolimus in order to provide data on long-term safety and efficacy. Patients were treated until it became commercially available in the respective indication or until documented tumor progression, unacceptable toxicity, any other reason or until study end on 31 May 2017, whichever came first.

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Core Inclusion:

  • Age ≥ 18 years old
  • Advanced (unresectable or ) -proven NETs of pancreatic origin
  • World health organization (WHO) Performance status of 0-2
  • Adequate bone marrow function as shown by:
  • (ANC) ≥ 1.5 x 109/L
  • ≥ 100 x 109/L
  • >9 g/dL
  • Adequate liver function as shown by:
  • Serum ≤ 1.5 x (ULN)
  • (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN. Patients with known liver metastases with an AST and ALT ≤ 5 x ULN
  • (INR) \<1.3 (INR \<3 in patients treated with anticoagulants)
  • Adequate renal function as shown by: Serum creatinine ≤ 1.5 x ULN
  • Fasting serum cholesterol ≤ 300 mg/dL or ≤ 7.75 mmol/L and fasting triglycerides ≤ 2.5 x ULN
  • Written obtained before any trial related activity and according to local guidelines.

Core Exclusion:

  • Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma were not eligible.
  • Following Amendment 1, patients with neuroendocrine tumors of GI or lung origin
  • Cytotoxic chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to enrollment
  • Hepatic artery embolization within the last two months or cryoablation or radiofrequency ablation of hepatic metastasis within two months of enrollment
  • Prior therapy with mTOR inhibitors (for example sirolimus, temsirolimus, everolimus)
  • Patients with a known to everolimus or other rapamycin analogs (sirolimus, temsirolimus) or to its
  • Patients receiving chronic treatment with immunosuppressives
  • Uncontrolled diabetes mellitus as defined by fasting serum glucose >1.5 x ULN
  • Patients who had any severe and/or uncontrolled medical conditions such as:

Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction

≤ 6 months prior to enrollment, serious uncontrolled cardiac arrhythmia

  • Active or uncontrolled severe infection
  • A history of invasive fungal infections
  • Severe hepatic impairment ( class C)
  • Severely impaired lung function
  • Active bleeding diathesis
  • Patients with a known history of (HIV) seropositivity
  • No other prior or concurrent was allowed except for, adequately treated basal cell or squamous cell skin cancer, or other adequately treated in situ cancer, or any other cancer from which the patient had been disease free for ≥ 3 years
  • Patients within four weeks post-major surgery, open-biopsy, or significant traumatic injury to avoid wound healing complications. Minor procedures and percutaneous biopsies or placement of vascular access device required seven days prior to study entry
  • Female patients who were pregnant or nursing
  • Adults who were of who were not using effective methods. Adequate contraceptives were to be used throughout the trial and for eight weeks after last study drug administration in female patients. Women of child bearing potential must have had a negative serum pregnancy test within seven days prior to first administration of study drug
  • Patients who were unwilling to or unable to comply with the protocol

Extension Inclusion and Exclusion Criteria:

  • The patient must provide a signed Informed Consent Form (ICF) for the extension study prior to any study related procedures
  • Age ≥18 years old
  • Completion of the whole treatment period in the CRAD001K24133 study
  • Neuroendocrine tumor of gastrointestinal or pulmonary origin (pancreatic neuroendocrine tumors are excluded)
  • No tumor progression during therapy with everolimus during CRAD001K24133 study (checked via radiologically assessment)
  • No intolerable toxicity during therapy everolimus, or during combination therapy of everolimus and somatostatin analogues
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
246 participants (actual)

Study arms

  • Experimental
    Everolimus (RAD001)

    Participants received Everolimus 10 mg orally once daily until documented tumor progression, unacceptable toxicity or any other reason.

    Drug: Everolimus (RAD001)

Interventions

  • Everolimus was supplied as tablets of 5mg strength.

    Also known as: Afinitor

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths (Core)

    The number of participants with AEs, SAEs and deaths were assessed.

    Time frame: from the day of first treatment up to 19 months

  2. Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths During the Extension Phase (E1)

    The number of participants with AEs, SAEs and deaths were assessed.

    Time frame: from the first day of treatment in the extension up to 4 years

Secondary outcomes

  1. Investigator-assessed Progression Free Survival (PFS) (Core)

    PFS was defined as the time from the date of the first dose to the date of the first radiologically documented disease progression or death due to any cause. If a participant had not progressed or died at the study end date or when he/she received any further anti-neoplastic therapy, PFS was censored at the time of the last tumor assessment before the end of study date. Progression was defined,using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: from the day of first treatment up to 19 months

  2. Mean European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Score (Core)

    The EORTC QLQ-C30 contains 30 questions assessed by the participant. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (Fatigue, Pain, and Nausea and Vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but two questions have 4-point scales ranging from "Not at all" to "Very much." The two questions concerning global health status/ QOL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.

    Time frame: Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82

  3. Mean EORTC QLQ-G.I. NET21 Score (Core)

    The EORTC QLQ-G.I. NET21 contains 21 questions and has three defined multi-item symptom scales (endocrine - 3 questions, gastrointestinal - 5 questions, and treatment related side effects - 3 questions), two single item symptoms (bone/muscle pain and concern about weight loss), two psychosocial scales (social function - 3 questions and disease-related worries - 3 questions) and two other single items (sexuality and communication). For each of the 9 domains, final scores are transformed such that they range from 0-100, where higher scores indicate worsening.

    Time frame: Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82

  4. Number and Percentage of Participants With Ratings of 'no Problem, 'Some Problem' and 'Extreme Problem' in the EuroQol Five Dimensions Questionnaire (EQ-5D) (Core)

    The EQ-5D is divided into two distinct sections. The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Patients rate each of these items from "no problem," "some problem," or "extreme problem." A composite health index is then defined by combining the levels for each dimension. The second section of the questionnaire measures self-rated (global) health status utilizing a vertically oriented visual analogue scale where 100 represents the "best possible health state" and 0 represents the "worst possible health state." Respondents are asked to rate their current health by placing a mark along this continuum. The scores from each section are then transformed into a single health utility score. Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.

    Time frame: Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82

  5. Mean EQ-5D Visual Analogue Scale (VAS) Score (Core)

    The EQ-5D is divided into two distinct sections. The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Patients rate each of these items from "no problem," "some problem," or "extreme problem." A composite health index is then defined by combining the levels for each dimension. The second section of the questionnaire measures self-rated (global) health status utilizing a vertically oriented visual analogue scale where 100 represents the "best possible health state" and 0 represents the "worst possible health state." Respondents are asked to rate their current health by placing a mark along this continuum. The scores from each section are then transformed into a single health utility score. Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.

    Time frame: Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82

  6. Investigator-assessed Best Overall Response (Core)

    Best overall response was determined from the sequence of investigator overall lesions responses according to Response Evaluation Criteria in Solid Tumors (RECIST). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Progression, a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: from the start of treatment, every 12 weeks for the first year and then every 6 months up to 19 months

  7. Investigator-assessed Progression Free Survival (PFS) (E1)

    PFS was defined as the time from the date of the start of therapy in the extension study to the date of the first radiologically documented disease progression or death due to any cause. If a participant had not progressed or died at the analysis cut-off date or when he/she received any further anti-neoplastic therapy, PFS was censored at the time of the last adequate tumor evaluation before the cut-off date or the anti-neoplastic therapy start date.

    Time frame: from first date of treatment in the extension up to 4 years

  8. Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)

    The EORTC QLQ-C30 contains 30 questions assessed by the participant. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role, cognitive, emotional, and social); 3 symptom scales (Fatigue, Pain, and Nausea and Vomiting); and a global health status and QOL scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but two questions have 4-point scales ranging from "Not at all" to "Very much." The two questions concerning global health status and QOL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, changes are calculated as value at later time point minus value at baseline, and final scores are transformed such that they range from 0-100, where higher scores indicate better outcomes. A positive change from baseline indicates improvement.

    Time frame: baseline, every 12 weeks and up to 4 years

  9. Change in EORTC QLQ-G.I. NET21 Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)

    The EORTC QLQ-G.I. NET21 contains 21 questions and has three defined multi-item symptom scales (endocrine - 3 questions, gastrointestinal - 5 questions, and treatment related side effects - 3 questions), two single item symptoms (bone/muscle pain and concern about weight loss), two psychosocial scales (social function - 3 questions, disease-related worries - 3 questions) and two other single items (sexuality and communication). For each of the 9 domains, final scores are transformed such that they range from 0-100, where higher scores indicate worsening outcomes. A positive change from baseline indicates worsening.

    Time frame: baseline, every 12 weeks and up to 4 years

  10. Change in EuroQol Five Dimensions Questionnaire (EQ-5D) Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)

    The EQ-5D contains 2 sections:1st section has 1 item addressing each of 5 dimensions (mobility, self-care, usual activity, pain/discomfort, anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems, 1-3, respectively. A health state is defined by combining 1 level from each dimension. 243 health states are possible. Each state is referred to in a 5 digit code. E.g., state 11111 indicates no problems on any dimension, while state 11223 indicates no problems with mobility and self-care, some problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression. The 2nd section measures self-rated health status using a visual analogue scale (VAS) where 100 represents best possible health and 0 represents worst possible health. Patients are asked to rate their current health by placing a mark on the VAS. Scores from each section are then transformed into an overall score of 0 or 1, with 0= higher level of dysfunction.

    Time frame: baseline, every 12 weeks and up to 4 years

  11. Investigator-assessed Best Overall Response During the Extension Phase (E1)

    Best overall response was determined from the sequence of investigator overall lesions responses according to Response Evaluation Criteria in Solid Tumors (RECIST). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Progression, a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: from the start of treatment, every 12 weeks for the first year and then every 6 months up to 4 years

07

Results

Posted Nov 29, 2018

Participant flow

Core
Participant flow — Core
MilestonepNET (Core)Non-pNET (Core)Lung NET (E1)GI NET (E1)
Started12612000
Completed0000
Not completed12612000
Withdrew: Patients completed per protocol854400
Withdrew: Adverse event192300
Withdrew: Disease progression142600
Withdrew: Withdrawal by subject41700
Withdrew: Death3600
Withdrew: Lost to follow-up1200
Withdrew: Protocol deviation0100
Withdrew: Administrative problems0100
Extension
Participant flow — Extension
MilestonepNET (Core)Non-pNET (Core)Lung NET (E1)GI NET (E1)
Started00411
Completed0000
Not completed00411
Withdrew: Administrative problems0001
Withdrew: Patients completed per protocol0002
Withdrew: Disease progression0047
Withdrew: Adverse event0001

Outcome measures

PrimaryNumber and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths (Core)

The number of participants with AEs, SAEs and deaths were assessed.

Time frame:
from the day of first treatment up to 19 months
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths (Core)
ParticipantspNET (Core)Non-pNET (Core)
Adverse events90109
Serious adverse events2559
Deaths510
PrimaryNumber and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths During the Extension Phase (E1)

The number of participants with AEs, SAEs and deaths were assessed.

Time frame:
from the first day of treatment in the extension up to 4 years
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths During the Extension Phase (E1)
ParticipantsLung NET (E1)GI NET
AEs411
SAEs14
Deaths01
SecondaryInvestigator-assessed Progression Free Survival (PFS) (Core)

PFS was defined as the time from the date of the first dose to the date of the first radiologically documented disease progression or death due to any cause. If a participant had not progressed or died at the study end date or when he/she received any further anti-neoplastic therapy, PFS was censored at the time of the last tumor assessment before the end of study date. Progression was defined,using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
from the day of first treatment up to 19 months
Reported as:
Median · Months
Investigator-assessed Progression Free Survival (PFS) (Core)
MonthspNET (Core)Non-pNET (Core)
Investigator-assessed Progression Free Survival (PFS) (Core)7.62 (5.52 to 7.62)10.78 (8.77 to NA)
SecondaryMean European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Score (Core)

The EORTC QLQ-C30 contains 30 questions assessed by the participant. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (Fatigue, Pain, and Nausea and Vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but two questions have 4-point scales ranging from "Not at all" to "Very much." The two questions concerning global health status/ QOL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.

Time frame:
Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82
Reported as:
Mean · units on a scale
Mean European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Score (Core)
units on a scalepNET (Core)Non-pNET (Core)
Global health status/QOL, Baseline64.93 ± 20.94660.53 ± 21.497
Global health status/QOL, Week 463.15 ± 19.67358.91 ± 20.622
Global health status/QOL, Week 859.72 ± 21.30356.59 ± 20.417
Global health status/QOL,Week 2063.10 ± 22.38759.65 ± 17.663
Global health status/QOL, Week 3250.0 ± 26.35256.20 ± 20.297
Global health status/QOL, Week 4461.11 ± 9.62357.74 ± 25.205
Global health status/QOL, EOT up to Week 8261.40 ± 20.84748.86 ± 27.823
Physical functioning, Baseline79.89 ± 20.85072.97 ± 22.938
Physical functioning, week 477.02 ± 22.38068.62 ± 23.648
Physical functioning, week 876.22 ± 25.81067.48 ± 24.973
Physical functioning, week 2079.77 ± 18.21273.71 ± 21.351
Physical functioning, week 3268.00 ± 26.41571.62 ± 23.729
Physical functioning, week 4468.89 ± 13.87876.19 ± 22.602
Physical functioning, EOT up to week 8275.70 ± 24.50960.94 ± 28.037
Role functioning, Baseline75.28 ± 28.66367.27 ± 32.397
Role functioning, week 472.49 ± 28.36462.25 ± 30.483
Role functioning, week 871.83 ± 30.02558.14 ± 31.460
Role functioning, week 2079.76 ± 25.80358.33 ± 29.129
Role functioning, week 3266.67 ± 26.35255.26 ± 35.325
Role functioning, week 4461.11 ± 9.62366.67 ± 26.954
Role functioning, EOT up to week 8267.84 ± 31.78849.13 ± 33.212
Emotional functioning, Baseline74.79 ± 22.65067.20 ± 22.988
Emotional functioning, week 476.31 ± 20.99166.69 ± 25.380
Emotional functioning, week 873.38 ± 24.73064.02 ± 26.640
Emotional functioning, week 2076.19 ± 19.07263.16 ± 27.456
Emotional functioning, week 3281.67 ± 14.90761.11 ± 28.184
Emotional functioning, week 4475.00 ± 8.33365.67 ± 31.059
Emotional functioning, EOT up to week 8274.61 ± 23.60257.63 ± 25.841
Cognitive functioning, Baseline84.17 ± 19.63080.61 ± 23.842
Cognitive functioning, week 486.11 ± 20.05078.80 ± 23.708
Cognitive functioning, week 881.94 ± 21.80376.33 ± 27.418
Cognitive functioning, week 2083.93 ± 19.50178.65 ± 23.307
Cognitive functioning, week 3286.67 ± 18.25775.21 ± 24.445
Cognitive functioning, week 4494.44 ± 9.62384.52 ± 20.111
Cognitive functioning, EOT up to week 8281.35 ± 21.24173.46 ± 24.522
Social functioning, Baseline75.56 ± 28.24967.42 ± 28.989
Social functioning, week 478.71 ± 23.34767.80 ± 30.093
Social functioning, week 875.69 ± 24.69565.31 ± 29.396
Social functioning, week 2073.21 ± 24.14866.07 ± 29.977
Social functioning, week 3260.00 ± 27.88966.24 ± 32.329
Social functioning, week 4466.67 ± 0.00072.62 ± 31.082
Social functioning, EOT up to week 8275.10 ± 27.53352.89 ± 33.933
Fatigue, baseline31.30 ± 22.36142.39 ± 28.534
Fatigue, week 435.22 ± 22.88743.58 ± 28.035
Fatigue, week 836.91 ± 25.51548.86 ± 29.878
Fatigue, week 2034.29 ± 18.43044.44 ± 27.698
Fatigue, week 3242.22 ± 18.25748.72 ± 29.575
Fatigue, week 4437.04 ± 6.41538.89 ± 26.777
Fatigue, EOT up to week 8238.83 ± 24.89656.49 ± 30.474
Nausea and vomiting, Baseline11.25 ± 17.4429.46 ± 17.353
Nausea and vomiting, week 410.52 ± 15.9987.43 ± 14.995
Nausea and vomiting, week 89.59 ± 17.98410.34 ± 18.015
Nausea and vomiting, week 208.05 ± 15.1856.14 ± 12.048
Nausea and vomiting, week 326.67 ± 9.1295.98 ± 11.139
Nausea and vomiting, week 4411.11 ± 9.6234.76 ± 10.187
Nausea and vomiting, EOT up to week 829.69 ± 17.04815.80 ± 27.023
Pain, Baseline21.57 ± 24.58231.21 ± 31.535
Pain, week 425.91 ± 26.71630.88 ± 29.796
Pain, week 825.23 ± 27.97237.55 ± 32.372
Pain, week 2027.98 ± 22.24733.33 ± 32.581
Pain, week 3243.33 ± 27.88934.62 ± 32.977
Pain, week 4438.89 ± 9.62326.19 ± 30.462
Pain, EOT up to week 8227.33 ± 28.34343.90 ± 33.362
Dyspnea, Baseline16.11 ± 22.44824.32 ± 29.110
Dyspnea, week 417.80 ± 24.17126.14 ± 28.388
Dyspnea, week 821.00 ± 27.50229.12 ± 31.665
Dyspnea, week 2011.49 ± 18.42228.07 ± 30.072
Dyspnea, week 3213.33 ± 18.25735.90 ± 31.885
Dyspnea, week 4422.22 ± 19.24521.43 ± 28.063
Dyspnea, EOT up to week 8225.19 ± 30.22233.77 ± 30.824
Insomnia, Baseline24.72 ± 30.09328.18 ± 32.929
Insomnia, week 427.78 ± 29.32432.36 ± 30.769
Insomnia, week 832.88 ± 30.17129.02 ± 28.540
Insomnia, week 2424.14 ± 26.57235.09 ± 32.380
Insomnia, week 3226.67 ± 27.88933.33 ± 32.880
Insomnia, week 4822.22 ± 19.24528.57 ± 36.648
Insomnia, EOT up o week 8232.17 ± 31.28934.63 ± 32.643
Appetite loss, Baseline20.56 ± 30.61318.62 ± 29.365
Appetitie loss, week 425.16 ± 31.61821.90 ± 29.849
Appetitie loss, week 824.66 ± 30.94625.67 ± 31.623
Appetitie loss, week 2418.39 ± 27.58320.47 ± 27.998
Appetitie loss, week 3620.00 ± 18.25723.93 ± 30.540
Appetitie loss, week 4411.11 ± 19.24526.19 ± 29.753
Appetitie loss, EOT up to week 8224.14 ± 29.50533.77 ± 37.906
Constipation, Baseline13.06 ± 24.17513.21 ± 27.072
Constipation, week 411.00 ± 24.42711.33 ± 24.501
Constipation, week 810.50 ± 24.1377.58 ± 22.447
Constipation, week 206.90 ± 16.3778.77 ± 21.387
Constipation, week 320.00 ± 0.0004.27 ± 13.636
Constipation, week 440.00 ± 0.0002.38 ± 8.909
Constipation, EOT up to week 8212.79 ± 24.61110.39 ± 23.107
Diarrhea, Baseline19.89 ± 29.53536.67 ± 38.828
Diarrhea, week 420.92 ± 25.65838.19 ± 36.577
Diarrhea, week 827.40 ± 29.57642.42 ± 39.708
Diarrhea, week 2016.67 ± 21.27631.58 ± 29.828
Diarrhea, week 3213.33 ± 18.25740.17 ± 36.015
Diarrhea, week 4422.22 ± 19.24540.48 ± 37.390
Diarrhea, EOT up to week 8225.97 ± 32.09539.04 ± 38.639
Financial difficulties, Baseline18.77 ± 26.97516.52 ± 25.770
Financial difficulties, week 416.67 ± 24.84516.67 ± 27.010
Financial difficulties, week 819.44 ± 26.09116.86 ± 24.837
Financial difficulties, week 2021.43 ± 22.61619.88 ± 27.357
Financial difficulties, week 3240.00 ± 27.88921.37 ± 28.084
Financial difficulties, week 4422.22 ± 19.24519.05 ± 25.198
Financial difficulties, EOT up to week 8221.71 ± 27.89727.63 ± 30.496
SecondaryMean EORTC QLQ-G.I. NET21 Score (Core)

The EORTC QLQ-G.I. NET21 contains 21 questions and has three defined multi-item symptom scales (endocrine - 3 questions, gastrointestinal - 5 questions, and treatment related side effects - 3 questions), two single item symptoms (bone/muscle pain and concern about weight loss), two psychosocial scales (social function - 3 questions and disease-related worries - 3 questions) and two other single items (sexuality and communication). For each of the 9 domains, final scores are transformed such that they range from 0-100, where higher scores indicate worsening.

Time frame:
Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82
Reported as:
Mean · units on a scale
Mean EORTC QLQ-G.I. NET21 Score (Core)
units on a scalepNET (Core)Non-pNET (Core)
Endocrine, Baseline12.99 ± 20.37223.52 ± 23.771
Endocrine, week 413.21 ± 17.44017.85 ± 21.403
Endocrine, week 813.47 ± 17.29316.79 ± 20.216
Endocrine, week 2012.50 ± 12.51115.87 ± 21.067
Endocrine, week 3216.67 ± 14.34413.74 ± 17.978
Endocrine, week 440.00 ± NA7.14 ± 11.202
Endocrine, EOT up to week 829.49 ± 15.62715.20 ± 18.755
G.I., Baseline23.69 ± 20.18326.19 ± 21.328
G.I., week 423.02 ± 20.48823.39 ± 18.958
G.I., week 822.34 ± 18.39827.53 ± 21.341
G.I., week 2025.63 ± 14.05622.31 ± 18.837
G.I., week 3225.00 ± 11.38626.84 ± 19.879
G.I., week 440.00 ± NA20.95 ± 16.714
G.I., EOT up to week 8225.85 ± 19.89930.48 ± 24.484
Treatment, baseline9.26 ± 11.67518.44 ± 19.374
Treatment, week 417.72 ± 15.33722.22 ± 20.077
Treatment, week 816.18 ± 19.52820.27 ± 17.283
Treatment, week 2028.70 ± 21.49319.74 ± 19.755
Treatment, week 3227.78 ± 7.85724.49 ± 23.684
Treatment, week 4416.67 ± NA18.18 ± 18.936
Treatment, EOT up to week 8222.06 ± 21.70524.81 ± 21.735
Social function, Baseline39.56 ± 23.72147.42 ± 25.726
Social function, week 436.52 ± 26.29445.28 ± 27.483
Social function, week 838.35 ± 23.62946.49 ± 26.265
Social function, week 2040.28 ± 14.47242.66 ± 25.648
Social function, week 3238.89 ± 14.34448.54 ± 23.735
Social function, week 4433.33 ± NA40.08 ± 26.165
Social function, EOT up to week 8238.89 ± 25.05154.22 ± 28.428
Disease-related worries, Baseline43.10 ± 25.59953.94 ± 27.664
Disease-related worries, week 439.20 ± 28.56246.33 ± 28.165
Disease-related worries, week 840.56 ± 28.18347.32 ± 28.541
Disease-related worries, week 2037.50 ± 8.26746.83 ± 32.096
Disease-related worries, week 3238.89 ± 11.11153.51 ± 27.137
Disease-related worries, week 4433.33 ± NA44.05 ± 32.647
Disease-related worries, EOT up to week 8242.89 ± 28.87655.04 ± 31.667
Muscle/bone pain, Baseline26.67 ± 33.34729.66 ± 31.210
Muscle/bone pain, week 424.07 ± 29.96633.00 ± 31.956
Muscle/bone pain, week 831.18 ± 34.35733.33 ± 33.524
Muscle/bone pain, week 2041.67 ± 15.43034.52 ± 33.614
Muscle/bone pain, week 3250.00 ± 19.24540.35 ± 34.795
Muscle/bone pain, week 4433.33 ± NA26.19 ± 26.726
Muscle/bone pain, EOT up to week 8234.13 ± 28.97340.89 ± 33.141
Sexual function, Baseline35.46 ± 32.89939.32 ± 40.468
Sexual function, week 421.05 ± 26.19140.89 ± 40.483
Sexual function, week 828.79 ± 33.00743.92 ± 40.083
Sexual function, week 2033.33 ± 33.33338.10 ± 39.724
Sexual function, week 3211.11 ± 19.24529.17 ± 35.864
Sexual function, week 44—47.62 ± 46.576
Sexual function, EOT up to week 8225.81 ± 28.16648.94 ± 43.323
Communication function, Baseline7.58 ± 16.3259.88 ± 22.904
Communication function, week 48.18 ± 17.1796.46 ± 15.626
Communication function, week 812.22 ± 18.5359.69 ± 19.714
Communication function, week 2014.29 ± 17.81710.30 ± 19.108
Communication function, week 328.33 ± 16.6677.89 ± 19.658
Communication function, week 440.00 ± NA4.76 ± 12.105
Communication function, EOT up to week 8212.70 ± 22.02812.61 ± 23.214
Body image, Baseline15.90 ± 28.93222.43 ± 34.195
Body image, week 415.09 ± 27.39922.79 ± 31.239
Body image, week 821.51 ± 27.95326.10 ± 31.256
Body image, week 2016.67 ± 17.81730.30 ± 34.708
Body image, week 320.00 ± 0.00028.83 ± 33.483
Body image, week 440.00 ± NA30.95 ± 27.625
Body image, EOT up to week 8223.02 ± 32.50034.70 ± 37.449
SecondaryNumber and Percentage of Participants With Ratings of 'no Problem, 'Some Problem' and 'Extreme Problem' in the EuroQol Five Dimensions Questionnaire (EQ-5D) (Core)

The EQ-5D is divided into two distinct sections. The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Patients rate each of these items from "no problem," "some problem," or "extreme problem." A composite health index is then defined by combining the levels for each dimension. The second section of the questionnaire measures self-rated (global) health status utilizing a vertically oriented visual analogue scale where 100 represents the "best possible health state" and 0 represents the "worst possible health state." Respondents are asked to rate their current health by placing a mark along this continuum. The scores from each section are then transformed into a single health utility score. Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.

Time frame:
Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Ratings of 'no Problem, 'Some Problem' and 'Extreme Problem' in the EuroQol Five Dimensions Questionnaire (EQ-5D) (Core)
ParticipantspNET (Core)Non-pNET (Core)
Baseline, Mobility, No problem8476
Baseline, Mobility, Some problem3135
Baseline, Mobility, Extreme problem21
Baseline, Self-care, No problem100102
Baseline, Self-care, Some problem1510
Baseline, Self-care, Extreme problem2—
Baseline, Usual activities, No problem7160
Baseline, Usual activities, Some problem4346
Baseline, Usual actvities, Extreme problem46
Baseline, Pain/Discomfort, No problem5940
Baseline, Pain/discomfort, Some problem5266
Baseline, Pain/discomfort, Extreme problem67
Baseline, Anxiety/depression, No problem6553
Baseline, Anxiety/depression, Some problem4754
Baseline, Anxiety/depression, Extreme problem56
Week 4, Mobility, No problem7266
Week 4, Mobility, Some problem2737
Week 4, Mobility, Extreme problem21
Week 4, Self-care, No problem8986
Week 4, Self-care, Some problem1016
Week 4, Self-care, Extreme problem32
Week 4, Usual activities, No problem6655
Week 4, Usual activities, Some problem3142
Week 4, Usual activities, Extreme problem47
Week 4, Pain/discomfort, No problem3930
Week 4, Pain/discomfort, Some problem5864
Week 4, Pain/discomfort, Extreme problem38
Week 4, Anxiety/depression, No problem5457
Week 4, Anxiety depression, Some problem4643
Week 4, Anxiety/depression, Extreme problem13
Week 8, Mobility, No problem4845
Week 8, Mobility, Some problem2437
Week 8, Mobility, Extreme problem23
Week 8, Self-care, No problem6170
Week 8, Self-care, Some problem715
Week 8, Self-care, Extreme problem61
Week 8, Usual activities, No problem4640
Week 8, Usual activities, Some problem2341
Week 8, Usual activties, Extreme problem45
Week 8, Pain/discomfort, No problem3425
Week 8, Pain/discomfort, Some problem3252
Week 8, Pain/discomfort, Extreme problem710
Week 8, Anxiety/depression, No problem4338
Week 8, Anxiety/depression, Some problem3041
Week 8, Anxiety/depression, Extreme problem18
Week 20, Mobility, No problem2637
Week 20, Mobility, Some problem317
Week 20, Mobility, Extreme problem—1
Week 20, Self-care, No problem2549
Week 20, Self-care, Some problem46
Week 20, Usual activities, No problem1830
Week 20 Usual activities, Some problem1022
Week 20, Usual activities, Extreme problem12
Week 20, Pain/discomfort, No problem1219
Week 20, Pain/discomfort, Some problem1634
Week 20, Pain/discomfort, Extreme problem12
Week 20, Anxiety/depression, No problem1627
Week 20, Anxiety/depression, Some problem1223
Week 20, Anxiety/depression, Extreme problem15
Week 32, Mobility, No problem325
Week 32, Mobility, Some problem212
Week 32, Mobility, Extreme problem—2
Week 32, Self-care, No problem532
Week 32, Self-care, Some problem—3
Week 32, Self-care, Extreme problem—2
Week 32, Usual activities, No problem422
Week 32, Usual activities, Some problem114
Week 32, Usual activities, Extreme problem—3
Week 32, Pain/discomfort, No problem110
Week 32, Pain/discomfort, Some problem427
Week 32, Pain/discomfort, Extreme problem—2
Week 32, Anxiety/depression, No problem420
Week 32, Anxiety/depression, Some problem114
Week 32, Anxiety/depression, Extreme problem—5
Week 44, Mobility, No problem29
Week 44, Mobility, Some problem14
Week 44, Mobility, Extreme problem—1
Week 44, Self-care, No problem312
Week 44, Self-care, Some problem—2
Week 44, Usual activities, No problem—6
Week 44, usual activities, Some problem37
Week 44, Pain/discomfort, No problem—6
Week 44, Pain/discomfort, Some problem38
Week 44, Anxiry/depression, No problem17
Week 44, Anxiety/depression, Some problem26
Week 44, Anxiety/depression, Extreme problem—1
EOT up to Week 82, Mobility, No problem5942
EOT up to Week 82, Mobility, Some problem2331
EOT up to Week 82, Mobility, Extreme problem44
EOT up to Week 82, Self-care, No problem6956
EOT up to Week 82, Self-care, Some problem1219
EOT up to Week 82, Self-care, Extreme problem21
EOT up toWeek 82, Usual activities, No problem5429
EOT up to Week 82, Usual activities, Some problem2436
EOT up to Week 82, Usual activities, Extreme prob.511
EOT up to Week 82, Pain/discomfort, No problem4318
EOT up to Week 82, Pain/discomfort, Some problem3648
EOT up to Week 82, Pain/discomfort, Extreme prob.511
EOT up to Week 82, Anxiety/depression, No problem4831
EOT up to Week 82, Anxiety/depression, Some prob.3340
EOT up toWeek 82, Anxiety/depression, Extreme prob36
SecondaryMean EQ-5D Visual Analogue Scale (VAS) Score (Core)

The EQ-5D is divided into two distinct sections. The first section includes one item addressing each of five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Patients rate each of these items from "no problem," "some problem," or "extreme problem." A composite health index is then defined by combining the levels for each dimension. The second section of the questionnaire measures self-rated (global) health status utilizing a vertically oriented visual analogue scale where 100 represents the "best possible health state" and 0 represents the "worst possible health state." Respondents are asked to rate their current health by placing a mark along this continuum. The scores from each section are then transformed into a single health utility score. Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.

Time frame:
Baseline, weeks 4, 8, 20, 32, 44, and end of treatment (EOT) up to week 82
Reported as:
Mean · units on a scale
Mean EQ-5D Visual Analogue Scale (VAS) Score (Core)
units on a scalepNET (Core)Non-pNET (Core)
Baseline68.8 ± 19.9063.9 ± 19.09
Week 469.3 ± 18.0663.8 ± 18.78
Week 864.6 ± 21.7761.2 ± 18.65
Week 2067.4 ± 19.5864.6 ± 15.51
Week 3242.6 ± 24.6762.0 ± 17.65
Week 4466.7 ± 15.2868.6 ± 18.71
EOT up to Week 8266.5 ± 20.6455.3 ± 23.02
SecondaryInvestigator-assessed Best Overall Response (Core)

Best overall response was determined from the sequence of investigator overall lesions responses according to Response Evaluation Criteria in Solid Tumors (RECIST). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Progression, a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
from the start of treatment, every 12 weeks for the first year and then every 6 months up to 19 months
Reported as:
Count of participants · Participants
Investigator-assessed Best Overall Response (Core)
ParticipantspNET (Core)Non-pNET (Core)
Partial response (PR)21
Stable disease (SD)7484
Progressive disease (PD)98
Unknown4127
Objective response rate (complete response or PR)21
SecondaryInvestigator-assessed Progression Free Survival (PFS) (E1)

PFS was defined as the time from the date of the start of therapy in the extension study to the date of the first radiologically documented disease progression or death due to any cause. If a participant had not progressed or died at the analysis cut-off date or when he/she received any further anti-neoplastic therapy, PFS was censored at the time of the last adequate tumor evaluation before the cut-off date or the anti-neoplastic therapy start date.

Time frame:
from first date of treatment in the extension up to 4 years
Reported as:
Median · Days
Investigator-assessed Progression Free Survival (PFS) (E1)
DaysLung NET (E1)GI NET (E1)
Investigator-assessed Progression Free Survival (PFS) (E1)159 (10 to 1074)655 (9 to NA)
SecondaryChange in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)

The EORTC QLQ-C30 contains 30 questions assessed by the participant. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role, cognitive, emotional, and social); 3 symptom scales (Fatigue, Pain, and Nausea and Vomiting); and a global health status and QOL scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but two questions have 4-point scales ranging from "Not at all" to "Very much." The two questions concerning global health status and QOL have 7 point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, changes are calculated as value at later time point minus value at baseline, and final scores are transformed such that they range from 0-100, where higher scores indicate better outcomes. A positive change from baseline indicates improvement.

Time frame:
baseline, every 12 weeks and up to 4 years
Reported as:
Mean · score on a scale
Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)
score on a scaleLung NET (E1)GI NET
Global health status/QoL0.00 ± NA-0.00 ± 11.785
Functional scale: Physical functioning6.67 ± NA0.00 ± 7.303
Functional scale: Role functioning-16.67 ± NA5.56 ± 22.771
Functional scale: Emotional functioning-25.00 ± NA-1.85 ± 17.003
Functional scale: Cognitive functioning-66.67 ± NA-16.67 ± 21.082
Functional scale: Social functioning0.00 ± NA-8.33 ± 9.129
Symptom scale: Fatigue0.00 ± NA-3.70 ± 22.951
Symptom scale: Nausea and vomiting0.00 ± NA0.00 ± 18.257
Symptom scale: Pain0.00 ± NA16.67 ± 27.889
Symptom scale: Dyspnea0.00 ± NA-5.56 ± 13.608
Symptom scale: Insomnia33.33 ± NA11.11 ± 17.213
Symptom scale: Appetite loss0.00 ± NA0.00 ± 21.082
Symptom scale: Constipation0.00 ± NA5.56 ± 25.092
Symptom scale: Diarrhea0.00 ± NA-16.67 ± 45.947
Symptom scale: Financial difficulties-33.33 ± NA16.67 ± 18.257
SecondaryChange in EORTC QLQ-G.I. NET21 Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)

The EORTC QLQ-G.I. NET21 contains 21 questions and has three defined multi-item symptom scales (endocrine - 3 questions, gastrointestinal - 5 questions, and treatment related side effects - 3 questions), two single item symptoms (bone/muscle pain and concern about weight loss), two psychosocial scales (social function - 3 questions, disease-related worries - 3 questions) and two other single items (sexuality and communication). For each of the 9 domains, final scores are transformed such that they range from 0-100, where higher scores indicate worsening outcomes. A positive change from baseline indicates worsening.

Time frame:
baseline, every 12 weeks and up to 4 years
Reported as:
Mean · units on a scale
Change in EORTC QLQ-G.I. NET21 Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)
units on a scaleLung NET (E1)GI NET
Social function11.11 ± NA7.41 ± 22.951
Disease-related worries44.44 ± NA-0.93 ± 7.384
Sexual function—50.00 ± 43.033
Communicative functioning0.00 ± NA11.11 ± 17.213
Endocrine scale11.11 ± NA5.56 ± 18.257
G.I. scale0.00 ± NA14.44 ± 23.633
Treatment scale-16.67 ± NA5.56 ± 12.423
Muscle/bone pain symptom—33.33 ± 29.814
Body image0.00 ± NA0.00 ± 21.082
SecondaryChange in EuroQol Five Dimensions Questionnaire (EQ-5D) Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)

The EQ-5D contains 2 sections:1st section has 1 item addressing each of 5 dimensions (mobility, self-care, usual activity, pain/discomfort, anxiety/depression). Each dimension has 3 levels: no problems, some problems, extreme problems, 1-3, respectively. A health state is defined by combining 1 level from each dimension. 243 health states are possible. Each state is referred to in a 5 digit code. E.g., state 11111 indicates no problems on any dimension, while state 11223 indicates no problems with mobility and self-care, some problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression. The 2nd section measures self-rated health status using a visual analogue scale (VAS) where 100 represents best possible health and 0 represents worst possible health. Patients are asked to rate their current health by placing a mark on the VAS. Scores from each section are then transformed into an overall score of 0 or 1, with 0= higher level of dysfunction.

Time frame:
baseline, every 12 weeks and up to 4 years
Reported as:
Mean · units on a scale
Change in EuroQol Five Dimensions Questionnaire (EQ-5D) Score at the End of Treatment From Baseline (Baseline = First Day of Treatment in the Extension) (E1)
units on a scaleLung NET (E1)GI NET
Composite health index7.26 ± NA-8.58 ± 13.302
Self-rated health status-10.00 ± NA-4.17 ± 21.479
SecondaryInvestigator-assessed Best Overall Response During the Extension Phase (E1)

Best overall response was determined from the sequence of investigator overall lesions responses according to Response Evaluation Criteria in Solid Tumors (RECIST). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Progression, a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
from the start of treatment, every 12 weeks for the first year and then every 6 months up to 4 years
Reported as:
Count of participants · Participants
Investigator-assessed Best Overall Response During the Extension Phase (E1)
ParticipantsLung NET (E1)GI NET
Complete response00
Partial response01
Stable disease27
Progressive disease23
Unknown00

Adverse events

Collected over up to 19 month for the core and up to 4 years for the extension. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
pNET (Core)—25/123 (20.3%)73/123 (59.3%)
Non-pNET (Core)—59/117 (50.4%)89/117 (76.1%)
Lung NET (E1)—1/4 (25%)4/4 (100%)
GI NET (E1)—4/11 (36.4%)11/11 (100%)
Most frequent serious events
Showing 10 of 116
Most frequent serious events
EventpNET (Core)Non-pNET (Core)Lung NET (E1)GI NET (E1)
AnaemiaBlood and lymphatic system disorders1/1233/1171/40/11
Cardiac failureCardiac disorders1/1232/1171/40/11
Pleural effusionRespiratory, thoracic and mediastinal disorders0/1231/1171/40/11
Retinal vascular thrombosisEye disorders0/1230/1170/41/11
Abdominal herniaGastrointestinal disorders0/1230/1170/41/11
Abdominal painGastrointestinal disorders1/1235/1170/41/11
ConstipationGastrointestinal disorders0/1230/1170/41/11
Inguinal herniaGastrointestinal disorders0/1230/1170/41/11
DeathGeneral disorders0/1230/1170/41/11
General physical health deteriorationGeneral disorders2/1237/1170/41/11
Most frequent other events
Showing 10 of 103
Most frequent other events
EventpNET (Core)Non-pNET (Core)Lung NET (E1)GI NET (E1)
ConstipationGastrointestinal disorders0/1234/1172/41/11
FlatulenceGastrointestinal disorders0/1231/1172/43/11
BronchitisInfections and infestations1/1232/1172/40/11
NasopharyngitisInfections and infestations2/1235/1172/45/11
Abdominal painGastrointestinal disorders4/12310/1170/45/11
HypertensionVascular disorders5/1236/1170/45/11
Oedema peripheralGeneral disorders5/12315/1170/44/11
Back painMusculoskeletal and connective tissue disorders0/1236/1170/44/11
DiarrhoeaGastrointestinal disorders10/12334/1170/43/11
AnaemiaBlood and lymphatic system disorders7/12310/1171/43/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)pNET (Core)Non-pNET (Core)Total
Mean59.3 ± 13.0464.4 ± 9.2861.8 ± 11.62
Sex: Female, Male
Sex: Female, Male(Participants)pNET (Core)Non-pNET (Core)Total
Female5861119
Male6859127
08

Study locations

11 sites
  • Novartis Investigative Site
    Berlin, 10098, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Homburg, 66421, Germany
  • Novartis Investigative Site
    Kassel, 34125, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Osnabrück, 49076, Germany
  • Novartis Investigative Site
    Weiden, 92637, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2012
First posted
May 9, 2012
Start
Apr 27, 2011
Primary completionActual
Aug 9, 2016
CompletionActual
Aug 9, 2016
Results first posted
Nov 29, 2018
Last update
Nov 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01595009
Responsible party
Sponsor
First posted
May 9, 2012
Start date
Apr 27, 2011
Primary completion
Aug 9, 2016
Completion
Aug 9, 2016
Results posted
Nov 29, 2018
Last update
Nov 29, 2018

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion